It has been documented that PARP1 can be regarded as a potential biomarker and therapeutic target for ischemic diseases, cardiac hypertrophy, diabetes, inflammation or neuronal death and some cancers (e.g., ovarian, breast and oral) [4,5]. The gene discussed is PARP1; the disease is cancer.